Samsung Biologics
OverviewSuggest Edit
Samsung Biologics is a contract development and manufacturing organization. It provides cell-line development to commercial manufacturing of drug substances and products. The company offers cGMP (Current Good Manufacturing Practice) facilities providing clinical and commercial products based on mammalian cell culture.
| Type | Public | |
| Founded | 2011 | |
| HQ | KR | Map |
| Website | samsungbiologics.com | |
| Employee Ratings | More | |
| Overall Culture | D | More |
Recent NewsAll News
- Samsung Biologics Reports Third Quarter 2021 Financial Results
- Enzolytics Inc. and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies
- Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA
- Samsung Biologics Reports Second Quarter 2021 Financial Results
Key People/Management at Samsung Biologics
John Rim
President & CEO
Dong Joong Kim
Senior Vice President & Managing Director
Seok Woo Jeong
Independent Director
Jo Kwon
Independent Director
Kun Nyoung
Independent Director
Eunice Kyunghee Kim
Independent Director
Samsung Biologics Financials and Metrics
Samsung Biologics Revenue
Market capitalization (10-Nov-2021) | 54.2t |
Closing stock price (10-Nov-2021) | 820.0k |
Samsung Biologics's current market capitalization is ₩54.2 t.
Samsung Biologics Cybersecurity Score
Samsung Biologics Environment, Social & Governance (ESG) Ratings
Samsung Biologics Online and Social Media Presence
735 Twitter followers
Samsung Biologics has 735 Twitter Followers. The number of followers has increased 62.5% month over month and increased 80.1% quarter over quarter
Samsung Biologics's Trends
Samsung Biologics Company Culture
Overall Culture
D
57/100
CEO Rating
F
50/100
Compensation
D
55/100
Samsung Biologics News and Updates
October 26, 2021
Samsung Biologics Reports Third Quarter 2021 Financial Results
Q3'21 revenue of KRW 450.7 billion increased 64% compared to Q3'20. Q3'21 operating profit of KRW 167.4 billion increased 196% compared to Q3'20. Stable supply, strong operational excellence and a high utilization rate across all plants. Active investment on expansion, pre-sales...
October 07, 2021
Enzolytics Inc. and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies
Enzolytics Inc. to leverage Samsung Biologics' development and manufacturing expertise to advance both Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies to IND. Samsung Biologics to offer a seamless, end-to-end CDMO service with support from its San Francisco R&D Center. COLLEGE...
September 22, 2021
Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA
INCHEON, South Korea, Sept. 22, 2021 /PRNewswire/ -- Samsung Biologics, a global contract development and manufacturing organization (CDMO), introduced its proprietary technology platform, S-CellerateTM, at the BioProcess International Conference (BPI 2021) to offer clients an integrated...
July 27, 2021
Samsung Biologics Reports Second Quarter 2021 Financial Results
Q2'21 revenue of KRW 412.2 billion increased 34% compared to Q2'20. Q2'21 operating profit of KRW 166.8 billion increased 105.7% compared to Q2'20. Stable business operations and a high utilization rate across all plants Continuous investments to deliver the company's future growth plans...
July 20, 2021
Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody Immunotherapy
Kineta to leverage Samsung Biologics' development and manufacturing expertise to advance KVA12.1 to IND Samsung Biologics San Francisco R&D center and South Korea headquarters to offer a seamless, end-to-end CDMO service INCHEON, South Korea and SEATTLE, July 20, 2021 /PRNewswire/ --...
May 31, 2021
Samsung Biologics to add mRNA vaccine drug substance manufacturing suite to expand portfolio of services
Samsung Biologics, a global leading CDMO, will add mRNA vaccine DS production capability to its existing facility by the first half of 2022 The addition will enable Samsung Biologics to provide end-to-end mRNA vaccine manufacturing services from bulk drug substance to aseptic fill/finish...
Samsung Biologics Frequently Asked Questions
When was Samsung Biologics founded?
Samsung Biologics was founded in 2011.
Who are Samsung Biologics key executives?
Samsung Biologics's key executives are John Rim, Dong Joong Kim and Seok Woo Jeong.
How many employees does Samsung Biologics have?
Samsung Biologics has 3,247 employees.
Who are Samsung Biologics competitors?
Competitors of Samsung Biologics include WuXi Biologics, Pharmaron and Kindeva Drug Delivery.
Where are Samsung Biologics offices?
Samsung Biologics has an office in.
How many offices does Samsung Biologics have?
Samsung Biologics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies